Wockhardt Limited · NSE:WOCKPHARMA
Wockhardt — Investor Presentation (May 2013)
26 slides from Wockhardt's investor presentation, May 2013

Slide 1: Wockhardt Limited Investor Presentation
Wockhardt Limited Investor Presenta,on By Dr. Murtaza Khorakiwala Managing Director May 2013

Slide 2: Safe Harbor Statement
Safe Harbor Statement • Except for historical informa,on contained herein, statements in this communica,on, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will con,nue”, “an,cipate”, “es,mate”, “intend”, “plan”, “contemplate”, “seek

Slide 3: Introduction to Wockhardt: Key Business Dynamics
Introduc4on to Wockhardt Key Business Dynamics

Slide 4: Wockhardt Today
Wockhardt Today UK, Ireland, France, Switz. USA Direct Opera4ons in India, USA Mexico India and Europe 7900 Associates employed in 21 countries Wockhardt Direct ROW opera4ons opera4ons Investor Presenta4on May 2013 4

Slide 5: Wockhardt Today: Manufacturing Locations
Wockhardt Today UK Ireland 9 sites Chicago in India Baddi 12 Manufacturing Loca4ons globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formula,ons APIs Investor Presenta4on May 2013 5

Slide 6: Wockhardt Today: R&D Centers
Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presenta4on May 2013 6

Slide 7: FY13 / Q4 Results
FY13 / Q4 Results TWOCKHARDI

Slide 8: FY13 & Q4 Results - Note
FY13 & Q4 Results -‐ Note • The results discussed in the following slides have been normalized for the following for all the previous compara,ve periods 1. Nutri,on Business Revenues and Profits and 2. Research & Development Costs Investor Presenta4on May 2013 8

Slide 9: FY13 Results (Annual)
FY13 Results (Annual) TWOCKHARDI

Slide 10: Sales – Growth of 29% over FY12
Sales – Growth of 29% over FY12 Rs.crore Growth of 29% in FY13 over FY12 Investor Presenta4on May 2013 10

Slide 11: EBITDA – Growth of 60% over FY12
EBITDA – Growth of 60% over FY12 Rs.crore Growth of 60% in FY13 over FY12 Investor Presenta4on May 2013 11

Slide 12: Adj. PAT Growth of 100% over FY12
Adj. PAT Growth of 100% over FY12 Rs.crore Growth of 100% in FY13 over FY12 Investor Presenta4on May 2013 12

Slide 13: Research
Research Investor Presenta4on May 2013 13

Slide 14: Strong Balance Sheet
Strong Balance Sheet Rs.crore Investor Presenta4on May 2013 14

Slide 15: Stronger Financial Parameters
Stonger Financial Parameters Investor Presenta4on May 2013 15

Slide 16: Financial Highlights
Financial Highlights • Free Cash Flow from opera,ons over Rs. 1,400 Crores for FY2013 (before capex and loan repayment). • Exit from CDR on target. • Total Debt (including Preference shares redemp,on) repaid during the year in excess of Rs.1,800 Crores. • Net interest cost stand at around 4.6% on an

Slide 17: Q4FY13 Results
Q4AFY13 Results TWOCKHARDI

Slide 18: Sales – Growth of 26% over Q4FY12
Sales – Growth of 26% over Q4FY12 Growth of 26% over Q4FY12 Investor Presenta4on May 2013 18

Slide 19: EBITDA – Growth of 37% over Q4FY12
EBITDA – Growth of 37% over Q4FY12 Growth of 37% over Q4FY12 13th Consecu4ve Quarter of Sequen4al Growth Investor Presenta4on May 2013 19

Slide 20: Adj. PAT – Stable Growth
Adj. PAT – Stable Growth Growth of 1% in Q4FY13 over Q4FY12 Investor Presenta4on May 2013 20

Slide 21: US Business: Profitable Growth
US Business: Profitable Growth • Growth of 52% (30% on $terms) over FY12. • 12 New Products launched in FY13. • 20 ANDAs filed during the year • 46 ANDAs pending approval. • Growth driven by niche launches made during the year • 18 products in US market at no.1 position and 17 products at no.2 positi

Slide 22: EU Operations: Strong UK Operations
EU Opera,ons: Strong UK Opera,ons UK Operations • UK operation grows by 24% (8% in £ terms) in FY13 against a stagnant market growth • 13 new product launches in FY13 of which 2 products being Day 1 launches • 16 new product filings in FY13. • No. 3 Generic company in UK • No. 2 in the hospital segm

Slide 23: Emerging Markets
Emerging Markets • Emerging Markets growth at 12% for FY2013. • Indian Business grew at 8% over FY12. • Restructuring of the India field force has been completed. • 21 new products were introduced in the Indian market, • ROW operations grew by 24% over FY12. • Mexico operations commenced. Investor P

Slide 24: Consistent Profitable Growth
Consistent Profitable Growth

Slide 25: Delivering Consistent Profits
Delivering Consistent Profits • R&D at the Strategic Core Research • Robust Product Pipeline • Direct Opera,ons in USA, UK , Ireland & India Globaliza,on • Strategic Alliances in Emerging Economies • Strong Management & Research Capabili,es Opera,onal • Focus on High Value Product Launches Excellence

Slide 26: For investor updates please visit www.wockhardt.com
For investor updates and communica4on please visit www.wockhardt.com For Informa,on please contact Tushar Mistry Tel.: +91 22 26596210 tmistry@wockhardt.com Investor Presenta,on May 2013 26
Source: Internet Archive copy of wockhardt.com
More decks from Wockhardt Limited
Investor Presentation (June 2026)36 slides · Jun 4, 2026
Investor Presentation (June 2025)34 slides · Jun 5, 2025
Investor Presentation (October 2024)44 slides · Oct 21, 2024
Investor Presentation (October 2024)43 slides · October 2024
Investor Presentation (February 2024)29 slides · Feb 26, 2024
Investor Presentation (February 2024)28 slides · February 2024